• Complex
  • Title
  • Keyword
  • Abstract
  • Scholars
  • Journal
  • ISSN
  • Conference
成果搜索

author:

Chen, L. (Chen, L..) [1] | Cheng, M.-M. (Cheng, M.-M..) [2] | Li, Y.-P. (Li, Y.-P..) [3] | Lin, S.-F. (Lin, S.-F..) [4] | Zheng, Q.-H. (Zheng, Q.-H..) [5] | Liu, Q.-Y. (Liu, Q.-Y..) [6]

Indexed by:

Scopus

Abstract:

The existence of cancer stem cells (CSCs) is considered to be the main reason for chemoresistance, metastasis and the ultimate failure of treatment in hepatocellular carcinoma (HCC ). However, there are a few chemical agents that may inhibit CSCs. The present study identified that 4,4'-bond secalonic acid D (4,4'-SAD), a compound isolated from the marine-derived fungus Penicillium oxalicum, inhibited the growth of side population (SP) cells isolated from human liver cancer cell lines PLC /PRF/5 and HuH-7 by attenuating the expression of ATP-binding cassette superfamily G member 2. Furthermore, the results of wound healing, Transwell, western blotting and reverse transcription-quantitative PCR assays demonstrated that 4,4'-SAD suppressed the invasion and migration of SP cells by downregulating matrix metallopeptidase 9 (MMP-9) and upregulating the antagonist tissue inhibitor of metalloproteinases 1 in vitro. Moreover, in vivo study results found that 4,4'-SAD had anti-lung metastasis efficacy via the decrease of MMP-9 expression in the H22 HCC model of Kunming mice. Therefore, the present study identified the potential of 4,4'-SAD as a promising candidate for the treatment of advanced liver cancer. © 2020 Spandidos Publications. All rights reserved.

Keyword:

4,4'-bond secalonic acid D; ATP-binding cassette superfamily G member 2; Hepatocellular carcinoma; Matrix metalloproteinase 9; Metastasis; SP cells

Community:

  • [ 1 ] [Chen, L.]Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, 350014, China
  • [ 2 ] [Chen, L.]Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, Fujian, 350002, China
  • [ 3 ] [Cheng, M.-M.]Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, Fujian, 350002, China
  • [ 4 ] [Li, Y.-P.]Institute of Biomedical and Pharmaceutical Technology, Fuzhou University, Fuzhou, Fujian, 350002, China
  • [ 5 ] [Lin, S.-F.]Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, 350014, China
  • [ 6 ] [Lin, S.-F.]Department of Thoracic Surgery, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, 350014, China
  • [ 7 ] [Zheng, Q.-H.]Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, 350014, China
  • [ 8 ] [Liu, Q.-Y.]Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, 350014, China

Reprint 's Address:

  • [Liu, Q.-Y.]Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital, Fujian Medical University Cancer HospitalChina

Show more details

Related Keywords:

Related Article:

Source :

Molecular Medicine Reports

ISSN: 1791-2997

Year: 2020

Issue: 6

Volume: 21

Page: 2624-2632

2 . 9 5 2

JCR@2020

3 . 4 0 0

JCR@2023

ESI HC Threshold:142

JCR Journal Grade:3

CAS Journal Grade:4

Cited Count:

WoS CC Cited Count:

SCOPUS Cited Count: 2

ESI Highly Cited Papers on the List: 0 Unfold All

WanFang Cited Count:

Chinese Cited Count:

30 Days PV: 0

Affiliated Colleges:

Online/Total:57/10115793
Address:FZU Library(No.2 Xuyuan Road, Fuzhou, Fujian, PRC Post Code:350116) Contact Us:0591-22865326
Copyright:FZU Library Technical Support:Beijing Aegean Software Co., Ltd. 闽ICP备05005463号-1